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ABSTRACT
Objective: To compare muscle strength (MS) and motor function in patients with Duchenne 
muscular dystrophy (DMD) receiving steroids for different times against the natural 
evolution of DMD described by Scott et al. Method: 90 patients with DMD (aged 5- 12 
years), receiving steroids for one to seven years, were evaluated by Medical Research 
Council Scale (MRC) and Hammersmith motor ability score. The relation between MS and 
motor abilities measurement from our data and Scott’s ones were ascertained statistically. 
Results: The relation between patient’s age and Hammersmith scores revealed decrease 
of 0.76 point per year for age against decrease of 2.23 points on Scott’s study. The relation 
between MRC scale and patient’s age showed decrease of 0.80 point per year of age 
against decrease of 3.65 points on Scott’s study. Conclusion: In patients with DMD aged 
five to 12 years the progression of the disease is delayed by steroids and the motor function 
is less reduced than muscular strength. 
Key words: Duchenne muscular dystrophy, steroids, muscle strength, motor ability, MRC 
scale, Hammersmith motor ability score.
Comparação da força e função motora em pacientes com distrofia muscular de 
Duchenne com ou sem corticoterapia
RESUMO
Objetivo: Comparar força muscular e função motora de pacientes com distrofia muscular 
de Duchenne (DMD) em corticoterapia com a evolução natural da doença descrita por 
Scott et al. Método: Noventa pacientes, entre 5 e 12 anos de idade, em corticoterapia 
por um até sete anos, foram avaliados quanto à força muscular (FM) (escala MRC) e função 
motora (Hammersmith motor ability score). A relação entre idade, FM e função motora e a 
comparação com o estudo de Scott et al foram determinadas estatisticamente. Resultados: 
a relação idade/escore Hammersmith diminuiu 0,76 pontos a cada ano de aumento da 
idade (2,23 pontos na história natural). A relação idade/MRC decresceu 0,80 pontos a cada 
ano de aumento da idade (3,65 pontos na história natural). Conclusão: Nos pacientes em 
corticoterapia, a progressão da doença é mais lenta que na evolução natural em todas as 
faixas etárias avaliadas, sendo a FM mais comprometida que a função motora. 
Palavras-chave: distrofia muscular de Duchenne, corticoterapia, força muscular, habilidade 
motora, escala Medical Research Council (MRC), Hammersmith motor ability score. Correspondence
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Duchenne muscular dystrophy (DMD) 
is an X-linked disease caused by a mutation 
in the dystrophin gene (locus Xp21.2)1,2 
that affects one in 3600-6000 live male 
births3. It has a progressive course that 
leads to the necessity of wheelchair around 
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10-12 years of age and in addition to the severe proximal 
muscle involvement it also presents with restrictive respi-
ratory insufficiency and myocardiopathy. The mean age at 
death that until 30-40 years ago was around 19,6 years of 
age, is increasing progressively due to the earlier diagno-
sis allowed by the molecular and immunohistochemical 
methods as well as by the improvement of the multidisci-
plinary management mainly represented by steroid thera-
py, cardiac and respiratory support, rehabilitation and or-
thopedic procedures, and psychosocial assistance. Pres-
ently, the life expectancy is around 30 years of age4 and it 
has been commented that the newly diagnosed patients 
are supposed to survive into their fourth decade with a 
reasonable quality of life5. 
Steroids, although palliative, are the only pharmaco-
logical approach that acts in slowing the progressive loss of 
muscle strength and motor ability in patients with DMD. 
They also delay the restrictive respiratory insufficiency, the 
scoliosis and in a lesser extent the cardiac involvement3,6-9.
Most of the studies on steroids therapy have empha-
sized its effect in prolonging ambulation3 but the amount 
and duration of the improvement in strength and motor 
ability have not been scored in details. Before the general 
use of steroids for DMD, Scott et al. (1982)10 established 
a profile of the natural progression of DMD which could 
serve as a reference base for the assessment of cases at 
varying ages and their response to therapy. They followed 
sequentially 61 boys with DMD for three years applying 
five different methods of motor and functional evaluation; 
the total muscle strength and the motor ability score were 
quantitatively determined using respectively the 6-point 
Medical Research Council Scale (MRC) grading and the 
functional scale based on 20 consecutive motor activi-
ties11. The result of the follow-up showed progressive de-
cline of muscle strength with age, a close correlation of 
total strength and the motor ability score, and a curvilin-
ear relation of muscle strength with walking time over 28 
and 150 feet. Therefore the objective of the present study 
was to evaluate the effect of the steroid therapy on the 
scores of muscle strength and motor ability measured in 
DMD patients with different times of treatment and to 
compare them with those reported by Scott et al in their 
description of the natural course of the disease. 
METHOD
Ninety patients aged 5 to 12 years diagnosed with 
DMD by molecular analysis or immunohistochemistry 
and Western blotting for dystrophin on muscular biopsy 
sample, were assessed by a physiotherapist for quantifying 
muscular strength and motor ability applying the Medical 
Research Council Scale (MRC) and Hammersmith mo-
tor ability score, respectively. All patients received ste-
roid therapy with deflazacort (0.9 mg/Kg/day) or pred-
nisolone (0.75 mg/kg/day in an intermittent course of 10 
days on, followed by 10 days off the drug) for a period 
varying from at least one to seven years (Table 1). No 
patients had been ever submitted to orthopedic surgi-
cal procedure and had ever interrupted the steroid in-
take. From October 2006 to February 2009 each patient 
was assessed only once by the same physiotherapist. The 
patients were evaluated in an unique opportunity by us-
ing the Hammersmith motor ability score which includes 
20 items scored from 0 to 40, and the Medical Research 
Council for testing the muscular strength which 30 mus-
cular groups, scored from 0 to 5 points10-12.
A concordance test was carried out through the par-
ticipation of a second physiotherapist for 80 patients and 
concordance was statistically good or very good. This 
study was approved by the Ethical Committee for re-
search projects analysis of our Institution under the num-
ber 0090/07, and all the parents of the 90 patients gave 
their informed consent.
For statistic analysis, the Pearson linear correlation 
(CI 95%) was used to compare the age at evaluation with 
the scores of Hammersmith motor ability and MRC. The 
results of the present study were compared to the results 
of the Scott’ study using a linear regression model with a 
confidence interval of the 95%.
RESULTS
The relation between the patient’s age at evaluation 
and the Hammersmith score in our study and that of 
Scott et al is shown in Fig 1. In the latter for each year of 
age increase the Hammersmith score showed a decrease 
of 2.23 points while in our study the decrease was of 0.76. 
In our study the relation between the age at evaluation 
and the Hammersmith score did not present a statisti-
cally significant difference (p=0.079). 
Table 1. Sample characteristics according to age and steroid 
therapy. 
Sample size (N) 90
Age in years at the beginning of steroid therapy
   Mean±standard deviation (years) 7.6±1.6
   Minimum-Maximum 4.1-10.9
Age in years at testing
   Mean±standard deviation (years) 9.3±1.6
   Minimum-Maximum 5.3-11.9
Duration of treatment (years)
   Medium (Q1-Q3) 1.1 (1.0-2.2)
   Minimum-Maximum 0.8-6.8
Type of steroid
   Deflazacort 58 (64.4%)
   Prednisolone 32 (35.6%)
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Comparing our data with those of Scott et al. using 
Pearson’s coefficient of correlation we observed that the 
loss of motor function in relation to the age in our pa-
tients was lesser than in Scott’s patients with statistical 
significance, therefore confirming that the boys treated 
with steroids had a slower disease progression (Table 2). 
The Table 3 shows that the difference between the two 
studies is directly related to the increase of the age. 
The relation between the patient’s age at evaluation 
and the MRC index in the two studies is demonstrated in 
Fig 2 in which it is possible to observe that in the study of 
Scott et al for each year of increase of the age at evalua-
tion there was a decrease of 3.65 in the MRC index; how-
ever in our patients we observed a decrease of 0.80 and 
the relation between the patient’s age and the MRC index 
was statistically significant (p=0.002). 
Comparing our data with those of Scott et al using 
Pearson’s coefficient of correlation we observed that in 
our patients the loss of muscular strength in relation to 
the age was lesser than in Scott’s patients with statistical 
significance, therefore confirming that the boys treated 
with steroids had a slower disease progression (Table 4). 
The Table 5 shows that the difference between the two ca-
suistics is directly related to the increase of the age. 
The Fig 3 shows, as it is illustrated by dispersion 
Fig 2. Scatter plot of the relation between MRC index and age at 
testing in both studies.
Fig 3. Scatter plot of the relation between Hammersmith scores 
and MRC index in both studies.
Table 2. Results of model for multiple regression for the adjusted relation between Hammersmith’ 
scores and patient’s age at testing in both studies.
Present study Scott et al. study
Regression model equation y = 38.5 – 0.76 × y = 42.5 – 2.23 ×
Coefficient of correlation  r = –0.19 r = –0.63
   95% Confidence Interval (CI) [–0.35 ; –0.01] [–0.74 ; –0.48]
   Sample size (N) 90 61
graphic, the relation between Hammersmith score and 
MRC index. In both studies it is possible to observe that 
the increase of MRC index and the Hammersmith score 
was directly related. However in the study of Scott et al., 
there was an increase of 1.1 in MRC index while in our 
study for each point of increase in Hammersmith score 
there was an increase of 0.45 in MRC index. The same 
Fig 1. Scatter plot of the relation between Hammersmith scores 
and patient’s age at testing in both studies.
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Table 3. Comparison between adjusted means of Hammersmith scores according to patient’s age at 
testing and comparison of the percentage difference of Hammersmith’ scores in both studies.
Age at testing
Hammersmith’ scores
Present study Scott et al. study
Difference percentage
Present/Scott et al.
5 years 34.7 31.4 10.5%
6 years 33.9 29.1 16.5%
7 years 33.2 26.9 23.4%
8 years 32.4 24.7 31.2%
9 years 31.6 22.4 41.1%
10 years 30.9 20.2 53.0%
11 years 30.1 18.0 67.2%
Table 4. Results of model for multiple regression for the adjusted relation between MRC index and 
patient’s age at testing in both studies.
Present study Scott et al. study
Regression model   zy 84.2 – 0.80 × y = 93.4 – 3.65 ×
Coefficient of correlation r = –0.32 r = –0.77
   95% Confidence interval (CI) [–0.47 ; –0.16] [–0.85 ; –0.67]
   Sample size (N) 90 61
Table 5. Comparison between adjusted values according to age at testing and comparison of the 
percentage difference of MRC index in both studies.
Age at testing
MRC values
Present study Scott et al. study
Difference percentage
Present/ Scott et al.
5 years 80.2 75.2 6.6%
6 years 79.4 71.5 11.0%
7 years 78.6 67.9 15.8%
8 years 77.8 64.2 21.2%
9 years 77 60.6 27.1%
10 years 76.2 56.9 33.9%
11 years 75.4 53.3 41.5%
MRC: Medical Research Council Scale.
Table 6. Results of model for regression for the adjusted relation between MRC index and the 
Hammersmith’ scores in both studies.
Present study Scott et al. study
Regression model y = 62.8 + 0.45 × y = 93.4 + 3.65 ×
Coefficient of correlation  r = 0.73 r = 0.83
   95% Confidence Interval (CI) [0.64 ; 0.80] [0.75 ; 0.89]
   Sample size (N) 90 61
MRC: Medical Research Council Scale.
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relation was maintained concerning the loss of muscular 
strength and motor function, therefore suggesting that 
the steroid therapy has a greater beneficial influence on 
motor function than on motor strength. 
Comparing our data with those of Scott et al. using 
Pearson’s coefficient of correlation we observed that the 
correlation between muscular strength and motor function 
was lower in our study than in the study of Scott et al.; how-
ever, we did not observe a statistical significance (Table 6). 
DISCUSSION
As it has been widely demonstrated in the literature13-19 
our study confirmed the beneficial effect of steroid therapy 
in slowing the progression of DMD. According to Bushby 
et al., it strongly urges to consider glucocorticoid therapy 
in all patients who have DMD3. Our study evaluated an 
expressive number of patients all under steroid therapy.
According to the study of Scott et al. that had the pru-
rpose of being a model for comparing the natural course 
of DMD against any changement of the course that could 
be promoved by any therapeutic resource, we compared 
in our study the relation between the age at the evaluation 
of the patient treated by steroids and Hammersmith score. 
We observed that the decrease of the scores that occurred 
accompanying the increase of the patients’ age was less-
er than that reported by Scott et al., as well as the loss of 
motor function whose difference with that reported in 
the natural course of DMD had statistical significance20.
Although our oldest patients have received lower 
scores that the youngest ones, the decrease of Hammer-
smith score did not present statistical significance. Based 
in this result we confirmed that concerning the motor 
function the disease progression in the treated patients 
is slower than that observed along the natural course and 
also that the Hammersmith scores show a stabilization 
along the different ages. For all ages the comparison be-
tween Hammersmith scores showed that our patients ob-
tained greater scores than those of the patients from Scott 
et al. and that the difference increases along the increase 
of the patients’ age. This finding is probably due to the 
fact that in the youngest boys the signs and symptoms of 
the disease are less evident and along the time the differ-
ence between non treated and treated patients become 
more evident.
The comparison between the patient’s age at evalua-
tion and the values of MRC índex showed an inverse re-
lation, i.e., the muscular strength decreases progressive-
ly along the child’s growth. The statistical analysis dem-
onstrated that the loss of muscular force in relation to 
the increase of the age was lesser in our patients than in 
those of Scott et al. For all periods of age considered the 
values of the MRC index obtained was superior to that 
obtained by the patients of Scott et al., and as greater the 
age was, as greater was the difference between the two 
studies. Again, this finding is probably due to the quicker 
and greater deterioration of the clinical status in the non 
treated patients. 
In both studies the correlation between Hammersmith 
scores and the values of MRC índex was strongly positive, 
therefore indicating that the motor function depends on 
the muscular strength. However in our study the motor 
function was less dependent on muscular strength than 
in the study of Scott et al., according to the results already 
exposed demonstrating that in the patients of different 
ages, the Hammersmith scores were less variable than the 
values of MRC index, in addition to the fact that for both 
tests the values were always superior to those described 
by Scott et al. According to Scott and Mawson, the cor-
relation between motor strenght and function must be 
carefully analysed because although both measures have 
to be considered related, they are not directly dependent 
due to the occurrence of a variety of possible dynamic 
compensations21. This finding has been observed in our 
study that demonstrated a quicker decrease of the MRC 
index in relation to the decrease of the functional score. 
This much better performance of motor function in rela-
tion to the muscular strength has also been emphasized 
by Kinali et al., in six patients initially evaluated with less 
than five years of age and followed-up for 30 months and 
more than five years of steroid therapy22. 
In conclusion our study of 90 patients with DMD 
demonstrated that the loss of muscular strength and 
motor function is slower in DMD patients under steroid 
therapy than along the natural course of the illness; in 
addition the loss of muscular strength is greater than the 
loss of motor function. 
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